Evidence map›Paper›PMID 38194289›Full record

ArticleJCI insight2024

Mechanisms of thyrotropin receptor-mediated phenotype variability deciphered by gene mutations and M453T-knockin model.

Kristiina Makkonen, Meeri Jännäri, Luís Crisóstomo, Matilda Kuusi, Konrad Patyra, Vladyslav Melnyk, Veli Linnossuo, Johanna Ojala, Rowmika Ravi, Christoffer Löf and 15 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 4 countries.

Kristiina MakkonenDepartment of Clinical Sciences, Faculty of Medicine, and.
Meeri JännäriDepartment of Clinical Sciences, Faculty of Medicine, and.
Luís CrisóstomoIntegrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.
Matilda KuusiIntegrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.
Konrad PatyraDepartment of Clinical Sciences, Faculty of Medicine, and.
Vladyslav MelnykDepartment of Clinical Sciences, Faculty of Medicine, and.
Veli LinnossuoDepartment of Clinical Sciences, Faculty of Medicine, and.
Johanna OjalaDepartment of Clinical Sciences, Faculty of Medicine, and.
Rowmika RaviDepartment of Clinical Sciences, Faculty of Medicine, and.
Christoffer LöfIntegrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.
Juho-Antti MäkeläIntegrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.
Päivi MiettinenNew Children's Hospital, Helsinki University Hospital, Helsinki, Finland.
Saila LaaksoNew Children's Hospital, Helsinki University Hospital, Helsinki, Finland.
Marja OjaniemiDepartment of Pediatrics and Adolescence, PEDEGO Research Unit and Medical Research Center, University and University Hospital of Oulu, Oulu, Finland.
Jarmo JääskeläinenDepartment of Pediatrics, Kuopio University Hospital, Kuopio, Finland.
Markku LaaksoInstitute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.
Filip BossowskiDepartment of Pediatrics, Endocrinology, Diabetes with a Cardiology Unit, Medical University in Białystok, Bialystok, Poland.
Beata SawickaDepartment of Pediatrics, Endocrinology, Diabetes with a Cardiology Unit, Medical University in Białystok, Bialystok, Poland.
Karolina StożekDepartment of Pediatrics, Endocrinology, Diabetes with a Cardiology Unit, Medical University in Białystok, Bialystok, Poland.
Artur BossowskiDepartment of Pediatrics, Endocrinology, Diabetes with a Cardiology Unit, Medical University in Białystok, Bialystok, Poland.
Gunnar KleinauCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, and.
Patrick ScheererCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, and.
FinnGen FinnGenInstitute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland.
Mary Pat ReeveInstitute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland.
Jukka KeroDepartment of Clinical Sciences, Faculty of Medicine, and.
University of Turku · FIMedical University of Białystok · PLHelsinki University Hospital · FIHumboldt-Universität zu Berlin · DEUniversity of Eastern Finland · FIUniversity of Helsinki · FIOulu University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical spectrum of thyrotropin receptor-mediated (TSHR-mediated) diseases varies from loss-of-function mutations causing congenital hypothyroidism to constitutively active mutations (CAMs) leading to nonautoimmune hyperthyroidism (NAH). Variation at the TSHR locus has also been associated with altered lipid and bone metabolism and autoimmune thyroid diseases. However, the extrathyroidal roles of TSHR and the mechanisms underlying phenotypic variability among TSHR-mediated diseases remain unclear. Here we identified and characterized TSHR variants and factors involved in phenotypic variability in different patient cohorts, the FinnGen database, and a mouse model. TSHR CAMs were found in all 16 patients with NAH, with 1 CAM in an unexpected location in the extracellular leucine-rich repeat domain (p.S237N) and another in the transmembrane domain (p.I640V) in 2 families with distinct hyperthyroid phenotypes. In addition, screening of the FinnGen database revealed rare functional variants as well as distinct common noncoding TSHR SNPs significantly associated with thyroid phenotypes, but there was no other significant association between TSHR variants and more than 2,000 nonthyroid disease endpoints. Finally, our TSHR M453T-knockin model revealed that the phenotype was dependent on the mutation's signaling properties and was ameliorated by increased iodine intake. In summary, our data show that TSHR-mediated disease risk can be modified by variants at the TSHR locus both inside and outside the coding region as well as by altered TSHR-signaling and dietary iodine, supporting the need for personalized treatment strategies.

Indexed as

HyperthyroidismIodineReceptors, ThyrotropinAnimalsHumansMiceMutationPhenotypeReceptors, G-Protein-CoupledIodineReceptors, G-Protein-CoupledReceptors, ThyrotropinTSHR protein, humanEndocrinologyGenetic diseasesGeneticsG protein–coupled receptorsThyroid disease

Identifiers

PMID38194289
PMCPMC11143923
OpenAlexW4392006337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.